Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 4,672 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Respiratory Therapy Clear all

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Lenalidomide; Drug
Lead sponsor: Jun Zhang; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NSCLC
Interventions: BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Glendale, California • Clermont, Florida • Orange City, Florida + 2 more

Conditions: Non-Small Cell Lung Cancer
Interventions: MEDI4736, PLACEBO; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 60
States / cities: Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Bosentan, Placebo, Sildenafil Citrate; Drug · Other
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Detroit, Michigan • Pittsburgh, Pennsylvania + 2 more

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions: Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Biological · Drug · Radiation + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Fractionated radiation therapy followed by chemotherapy; Radiation
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sleep Apnea
Interventions: Acetazolamide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Interventions: GDC-6036, Atezolizumab, Cetuximab, Bevacizumab, Erlotinib, GDC-1971, Inavolisib; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Duarte, California • La Jolla, California • Orange, California + 6 more

Conditions: Asthma
Interventions: Tiotropium Respimat®, Inhaled Corticosteroid/Long-acting beta-agonist; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years and older
Enrollment: 7,857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: White Plains, New York

Conditions: Sleep Apnea, Obstructive
Interventions: Ramelteon or Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 5
States / cities: Birmingham, Alabama • Palm Springs, California • Santa Monica, California + 2 more

Conditions: Lung Cancer
Interventions: PF-00299804, Placebo; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Arcadia, California • Skokie, Illinois

Conditions: Asthma
Interventions: QGE031, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Birmingham, Alabama • Kingwood, Texas • Plano, Texas

Conditions: Head and Neck Cancer
Interventions: porfimer sodium, Photdynamic Therapy (PDT); Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions: Antibiotic; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 34
States / cities: Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more

Conditions: Cystic Fibrosis
Interventions: Ataluren, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 6 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 21
States / cities: Birmingham, Alabama • Long Beach, California • Palo Alto, California + 16 more

Conditions: Cerebral Palsy, Hypoxia, Brain
Interventions: Aquatic therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 3 Years to 9 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: Salbutamol HFA-134a, Salbutamol HFA-152a; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 38
States / cities: North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more

Conditions: Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion, Stage IV Non-small Cell Lung Cancer
Interventions: Tamibarotene, Placebo; Drug
Lead sponsor: CytRx; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Rancho Mirage, California • Kansas City, Kansas • Hackensack, New Jersey

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions: LYL797; Biological
Lead sponsor: Lyell Immunopharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Scottsdale, Arizona • Santa Monica, California • New Haven, Connecticut + 15 more

Conditions: Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Carboplatin, Pemetrexed, Selpercatinib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 265
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Anaheim, California + 219 more

Conditions: Covid19
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Newark, New Jersey • Edinburg, Texas

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer
Interventions: Topotecan, Docetaxel; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Gated Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Inoperable NSCLC

A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Impact of Tiotropium Add-on Therapy in Patients With Asthma

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Study of Ataluren (PTC124™) in Cystic Fibrosis

Aquatic Therapy for Children With Neuromotor Deficits

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

A Study to Investigate LYL797 in Adults With Solid Tumors

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Effects of Pulmonary Hypertension Therapy in Atypical Pulmonary Arterial Hypertension

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer